Mumbai, India – January 28, 2025: Piramal Pharma Limited (NSE: PPLPHARMA, BSE: 543635) has announced its unaudited financial results for Q3 FY2024-25, reporting ₹2,204.22 crore in revenue and ₹3.68 crore in net profit. The company also appointed Ms. Nathalie Leitch as a Non-Executive, Non-Independent Director, strengthening its leadership team.
Key Financial Highlights – Q3 FY2024-25 (Consolidated)
- Revenue from Operations: ₹2,204.22 crore (YoY increase from ₹1,958.57 crore)
- Total Income: ₹2,216.35 crore
- Profit Before Tax (PBT): ₹66.80 crore
- Net Profit (PAT): ₹3.68 crore (compared to ₹10.11 crore in Q3 FY24)
- Earnings Per Share (EPS): ₹0.03 per share.
Nine-Month Performance (April – December 2024) (Consolidated)
- Total Revenue: ₹6,397.11 crore (YoY increase from ₹5,618.80 crore)
- Profit Before Tax (PBT): ₹141.84 crore
- Net Profit (PAT): ₹(62.37) crore (compared to ₹(83.45) crore loss in the previous period)
- EPS: ₹(0.47) per share.
Key Business Highlights
- Revenue Growth Across Segments:
- The pharmaceutical business saw a 12.5% YoY revenue increase.
- Expansion in contract development and manufacturing (CDMO) services.
- Steady demand for inhalation anesthetics and injectable drugs.
- Cost Management & Operational Efficiency:
- The cost of materials consumed at ₹805.44 crore, reflecting improved supply chain efficiency.
- Depreciation & amortization expenses stood at ₹196.81 crore.
- Finance costs remained steady at ₹103.31 crore.
- Appointment of Nathalie Leitch as Director:
- Extensive experience in the global pharmaceutical industry.
- Previously held leadership roles at Apotex, Fresenius Kabi, and Teva Pharmaceuticals.
- Expertise in generic drug development, R&D, and M&A.
Management Commentary
Nandini Piramal, Chairperson, Piramal Pharma Limited, stated:"Our Q3 results demonstrate continued revenue growth, and we are strengthening our leadership with the appointment of Ms. Leitch. We focus on expanding our CDMO business and enhancing operational efficiencies.".
Market Outlook & Investor Takeaways
- Improving financial stability despite net profit fluctuations.
- Leadership expansion to drive strategic growth and business development.
- Upcoming quarters will be crucial for profitability improvements and CDMO expansion.